This article is more than 5 years old. Information may no longer be current.

Allergan reports net loss for 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan reported a net loss attributable to ordinary shareholders of $4.3 billion, or $12.83 per basic share, in the fourth quarter of 2018 compared with a net income of $3 billion, or $9.21 per basic share, in the same quarter of 2017, according to a press release.

For the full year, Allergan reported a net loss attributable to ordinary shareholders of $5.1 billion, or $15.26 per basic share, compared with a net loss of $4.4 billion, or $13.19 per basic share, in 2017.

Net revenues totaled nearly $4.1 billion in the fourth quarter and $15.8 billion for the full year vs. $4.3 billion and $15.9 billion in the same time periods of 2017.

In the eye care division, product revenue was $587.3 million in the fourth quarter, a 12.6% decrease from $671.7 million in the fourth quarter of 2017. For the full year, total eye care product revenue was $2.2 billion vs. nearly $2.5 billion in 2017.

Restasis net revenue decreased 18.8% to $325 million in the fourth quarter and 15.2% to nearly $1.2 billion for the full year. Alphagan/Combigan net revenue decreased 0.5% for the year to $375.4 million, while Ozurdex net revenue increased 12.8% to $111 million in 2018.